First Edition: January 13, 2012

NewsGuard 100/100 Score

Today's headlines include reports that the Obama administration called Trustmark's proposed insurance rate increases "unreasonable" and called on the company to rescind them.   

Kaiser Health News: The Public Option Did Not Die
KQED's Sarah Varney, reporting as part of a partnership with Kaiser Health News, NPR and KQED, writes: "The much celebrated, and much maligned, public option may have died in Congress, but it's alive and well in California. Unique in the nation for having public health insurance plans that are run by counties, California has plans that stretch from San Francisco to the Mexican border and cover 2.5 million residents" (Varney, 1/12).

Kaiser Health News: Capsules: HHS Calls Trustmark's Rate Increases 'Unreasonable'; Insurer Begs To Differ
Now on Kaiser Health News' blog, Mary Agnes Carey reports: "The Department of Health and Human Services Thursday deemed a health insurer's proposed  premium increases in five states 'unreasonable' and called on the company to rescind the rates, issue refunds or justify the increase" (1/12).

Also on the blog, Andrew Villegas checks in on blogosphere chatter about physicians and "parsimonious care." He writes: "Yesterday on the main KHN site we had a round robin of experts talking about the American College of Physicians' latest update of its ethics manual. The manual encourages doctors to be 'parsimonious' in doling out health care. … After we talked to experts for the round robin, I also sauntered around the Internet looking for blog posts on the subject." He provides a sampling (1/13).

And, Jordan Rau reports that a group of industry experts said nearly half of quality measures fall short: "A group of health care experts and industry officials has rejected 45 percent of the quality measures the Centers for Medicare & Medicaid Services is considering to use in evaluating nursing homes, hospitals, diabetes facilities and other providers" (1/12). Check out what else is on the blog.

NPR: Biggest Bucks In Health Care Are Spent On A Very Few
Researchers from the Agency for Healthcare Research and Quality looked at the way people actually spend money on health care. They found that half the population spends practically nothing on health care in any given year, while a very few unlucky people account for the lion's share (Rovner, 1/12).

The New York Times: U.S. Seeks Rollback Of A Health Insurer's 'Excessive' Rate Increase
The Obama administration said Thursday that rate increases sought by a health insurance company were unreasonable, and it ordered the insurer to rescind them or justify its refusal to do so (Pear, 1/12).

The Wall Street Journal: Government Edges Toward The Debt Ceiling
The White House notified Congress on Thursday that the government was near its $15.194 trillion borrowing limit, ushering in the debut of procedural theater in which the debt limit will ultimately be raised even if Congress votes against it (Paletta, 1/13).

The Hill's Healthwatch: Study: Premiums Could Rise 25 Percent Without Insurance Mandate
Insurance premiums would rise by as much as 25 percent if the healthcare law is implemented without an individual mandate, according to a new analysis from the Robert Wood Johnson Foundation. … Without the mandate, according to the Robert Wood Johnson analysis, costs would rise and fewer people would be insured (Baker, 1/12).

Politico: Ahead Of South Carolina Primary: Mitt Romney Picks Up Pro-Life Rhetoric
Mitt Romney's beginning to stress his opposition to abortion rights -; the latest offensive-defense tactic from a candidate who's already under fire for his stance on the issue in South Carolina. At both voter rallies he held there, home of the next primary, Romney added language to his stump speech reminding voters he is pro-life. And the candidate, who's hoping this socially conservative state where he's hoping to score a third consecutive early state win on Jan. 21, says that's no mistake (Epstein and Summers, 1/12).

The Associated Press/Washington Post: IMS Health: Branded Lipitor Sales Leveling Off After Arrival Of 1st Generic Competition
Sales of Lipitor, the top-selling drug in history, have leveled off after a steep plunge following the start of U.S. generic competition. New figures from data firm IMS Health show that at the end of December, sales of Pfizer Inc.'s Lipitor were at just above a 37 percent market share (1/12).

The New York Times: CVS Settles Prescription Price Case
After more than two years of investigation, CVS Caremark agreed on Thursday to pay $5 million to settle charges by the Federal Trade Commission that the company had misrepresented the price of certain prescription drugs in one of its Medicare drug plans, causing many older consumers to pay significantly higher prices than advertised (Abelson and Singer, 1/12).

The Associated Press/Washington Post: CVS Caremark To Pay $5 Million To End FTC Investigation Into Inaccurate Drug Price Reports
The payment will be used to reimburse Medicare prescription drug beneficiaries who paid more than they expected for the drugs, and it ends a two-year investigation by the Federal Trade Commission. CVS Caremark said its Rx America business accidentally published incorrect drug price information on a site maintained by Medicare (1/12).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
RAND report: Hospital prices surge above Medicare rates in 2022